Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

被引:134
作者
Degott, C
Zafrani, ES
Callard, P
Balkau, B
Poupon, RE
Poupon, R
机构
[1] Hop St Antoine, Serv Hepatogastroenterol, AP Hop Paris, F-75571 Paris 12, France
[2] Hop Beaujon, Serv Anat & Cytol Pathol, Clichy, France
[3] Hop Henri Mondor, Serv Anat & Cytol Pathol, F-94010 Creteil, France
[4] Hop Tenon, Serv Anat & Cytol Pathol, F-75970 Paris, France
[5] INSERM, Unit 21, F-94807 Villejuif, France
关键词
D O I
10.1002/hep.510290444
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The semiquantitative histopathological analysis of the liver biopsies obtained before and after 4 years of ursodeoxycholic acid (UDCA) therapy in a cohort of primary biliary cirrhosis (PBC) patients is reported. The relationships between elementary histological lesions before treatment and their progression under therapy were assessed. At baseline, two independent groups of lesions, each of which participate in the development of fibrosis, were individualized, i.e., florid bile duct lesions and ductopenia on one hand and lymphocytic piecemeal necrosis, ductular proliferation, and lobular necroinflammatory changes on the other hand. Four years of UDCA therapy were associated with a significant decrease in the prevalence of florid interlobular bile duct (ILBD) lesions, of epithelioid granuloma (P <.001) without any aggravation in the severity of bile duct paucity. Lobular inflammation and necrosis markedly improved (P <.001) whereas the degree of severity of the lymphocytic piecemeal necrosis and ductular proliferation at entry and at 4 years were similar. Worsening of fibrosis was observed in 14 patients (12 of them had a one grade progression) whereas stabilization was noted in 30 of the remaining patients. Severity of both the lymphocytic piecemeal necrosis and lobular inflammation and necrosis at entry was significantly associated with the progression of fibrosis. The results suggest that UDCA therapy influences the process leading to bile duct destruction. Patients with severe lymphocytic piecemeal necrosis and lobular inflammation may need additional therapeutic intervention because they have increased risk of fibrosis progression.
引用
收藏
页码:1007 / 1012
页数:6
相关论文
共 21 条
[1]
Primary biliary cirrhosis autoimmune hepatitis overlap syndrome:: Clinical features and response to therapy [J].
Chazouillères, O ;
Wendum, D ;
Serfaty, L ;
Montembault, S ;
Rosmorduc, O ;
Poupon, R .
HEPATOLOGY, 1998, 28 (02) :296-301
[2]
CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236
[3]
COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5
[4]
Desmet V J, 1992, Prog Liver Dis, V10, P89
[5]
THE CANADIAN MULTICENTER DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF URSODEOXYCHOLIC ACID IN PRIMARY BILIARY-CIRRHOSIS [J].
HEATHCOTE, EJ ;
CAUCHDUDEK, K ;
WALKER, V ;
BAILEY, RJ ;
BLENDIS, LM ;
GHENT, CN ;
MICHIELETTI, P ;
MINUK, GY ;
PAPPAS, SC ;
SCULLY, LJ ;
STEINBRECHER, UP ;
SUTHERLAND, LR ;
WILLIAMS, CN ;
WITTSULLIVAN, H ;
WOROBETZ, LJ ;
MILNER, RA ;
WANLESS, IR .
HEPATOLOGY, 1994, 19 (05) :1149-1156
[6]
MEMBRANE DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2) ON HUMAN BILIARY EPITHELIAL-CELLS IN PRIMARY BILIARY-CIRRHOSIS [J].
JOPLIN, R ;
LINDSAY, JG ;
JOHNSON, GD ;
STRAIN, A ;
NEUBERGER, J .
LANCET, 1992, 339 (8785) :93-94
[7]
Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis [J].
Koga, H ;
Sakisaka, S ;
Ohishi, M ;
Sata, M ;
Tanikawa, K .
HEPATOLOGY, 1997, 25 (05) :1077-1084
[8]
LEHMAN EL, NONPARAMETRICS, V197, P233
[9]
Molecular aspects and the pathological basis of primary biliary cirrhosis [J].
Leung, PSC ;
VandeWater, J ;
Coppel, RL ;
Nakanuma, Y ;
Munoz, S ;
Gershwin, ME .
JOURNAL OF AUTOIMMUNITY, 1996, 9 (02) :119-128
[10]
URSODEOXYCHOLIC ACID IN THE TREATMENT OF PRIMARY BILIARY-CIRRHOSIS [J].
LINDOR, KD ;
DICKSON, ER ;
BALDUS, WP ;
JORGENSEN, RA ;
LUDWIG, J ;
MURTAUGH, PA ;
HARRISON, JM ;
WIESNER, RH ;
ANDERSON, ML ;
LANGE, SM ;
LESAGE, G ;
ROSSI, SS ;
HOFMANN, AF .
GASTROENTEROLOGY, 1994, 106 (05) :1284-1290